211 related articles for article (PubMed ID: 24235247)
1. Control-relevant erythropoiesis modeling in end-stage renal disease.
Chait Y; Horowitz J; Nichols B; Shrestha RP; Hollot CV; Germain MJ
IEEE Trans Biomed Eng; 2014 Mar; 61(3):658-64. PubMed ID: 24235247
[TBL] [Abstract][Full Text] [Related]
2. Simplification of an erythropoiesis model for design of anemia management protocols in end stage renal disease.
Nichols B; Shrestha RP; Horowitz J; Hollot CV; Germain MJ; Gaweda AE; Chait Y
Annu Int Conf IEEE Eng Med Biol Soc; 2011; 2011():83-6. PubMed ID: 22254256
[TBL] [Abstract][Full Text] [Related]
3. Greater potency of darbepoetin-α than erythropoietin in suppression of serum hepcidin-25 and utilization of iron for erythropoiesis in hemodialysis patients.
Shoji S; Inaba M; Tomosugi N; Okuno S; Ichii M; Yamakawa T; Kurihara S
Eur J Haematol; 2013 Mar; 90(3):237-44. PubMed ID: 23281632
[TBL] [Abstract][Full Text] [Related]
4. The anemia of chronic renal failure: pathophysiology and effects of recombinant erythropoietin.
Eschbach JW; Haley NR; Adamson JW
Contrib Nephrol; 1990; 78():24-36; discussion 37. PubMed ID: 2225841
[No Abstract] [Full Text] [Related]
5. Dose-related effects of recombinant human erythropoietin on erythropoiesis. Results of a multicenter trial in patients with end-stage renal disease.
Bommer J; Kugel M; Schoeppe W; Brunkhorst R; Samtleben W; Bramsiepe P; Scigalla P
Contrib Nephrol; 1988; 66():85-93. PubMed ID: 3292151
[No Abstract] [Full Text] [Related]
6. Darbepoetin alfa administered every other week maintains hemoglobin levels over 52 weeks in patients with chronic kidney disease converting from once-weekly recombinant human erythropoietin: results from simplify the treatment of anemia with Aranesp (STAAR).
Hertel J; Locay H; Scarlata D; Jackson L; Prathikanti R; Audhya P
Am J Nephrol; 2006; 26(2):149-56. PubMed ID: 16636531
[TBL] [Abstract][Full Text] [Related]
7. Evolution of recombinant human erythropoietin usage in clinical practice in the United States. Is there an optimal way to use rHuEPO?
Besarab A; McCrea JB
ASAIO J; 1993; 39(1):11-8. PubMed ID: 8439674
[No Abstract] [Full Text] [Related]
8. [The recovery of erythropoiesis after the short-term Recormon treatment of renal anemia].
Nikolaev AIu; Klepikov PV; Lashutin SV
Ter Arkh; 1992; 64(6):90-1. PubMed ID: 1440349
[No Abstract] [Full Text] [Related]
9. [Recombinant human erythropoietin in the treatment of the anemia of multiple myeloma with kidney failure].
Arenas Gracia M; Abad Gosálvez A; Colomina Avilés J; Pascual Pérez R; Ferriz Moreno P
An Med Interna; 1995 Apr; 12(4):187-8. PubMed ID: 7620064
[TBL] [Abstract][Full Text] [Related]
10. Once weekly versus twice weekly subcutaneous administration of recombinant human erythropoietin in patients on continuous ambulatory peritoneal dialysis.
Lui SF; Law CB; Ting SM; Li P; Lai KN
Clin Nephrol; 1991 Nov; 36(5):246-51. PubMed ID: 1752075
[TBL] [Abstract][Full Text] [Related]
11. Recombinant human erythropoietin in a patient with multiple myeloma and end-stage renal disease.
Holley JL; Nolan TA; Piraino B
Clin Nephrol; 1992 Mar; 37(3):145-7. PubMed ID: 1563119
[TBL] [Abstract][Full Text] [Related]
12. 2008 Japanese Society for Dialysis Therapy: guidelines for renal anemia in chronic kidney disease.
Tsubakihara Y; Nishi S; Akiba T; Hirakata H; Iseki K; Kubota M; Kuriyama S; Komatsu Y; Suzuki M; Nakai S; Hattori M; Babazono T; Hiramatsu M; Yamamoto H; Bessho M; Akizawa T
Ther Apher Dial; 2010 Jun; 14(3):240-75. PubMed ID: 20609178
[TBL] [Abstract][Full Text] [Related]
13. Anemia of chronic renal failure: treatment with erythropoietin.
Navarro M; Alonso A; Avilla JM; Espinosa L
Child Nephrol Urol; 1991; 11(3):146-51. PubMed ID: 1777893
[TBL] [Abstract][Full Text] [Related]
14. Body fat mass and serum leptin levels influence epoetin sensitivity in patients with ESRD.
Axelsson J; Qureshi AR; Heimbürger O; Lindholm B; Stenvinkel P; Bárány P
Am J Kidney Dis; 2005 Oct; 46(4):628-34. PubMed ID: 16183417
[TBL] [Abstract][Full Text] [Related]
15. Angiotensin converting enzyme inhibitors impair recombinant human erythropoietin induced erythropoiesis in patients with chronic renal failure.
Qureshi IZ; Abid K; Ambreen F; Qureshi AL
Saudi Med J; 2007 Feb; 28(2):193-6. PubMed ID: 17268695
[TBL] [Abstract][Full Text] [Related]
16. Darbepoetin alfa (KRN321) administered intravenously once monthly maintains hemoglobin levels in peritoneal dialysis patients.
Hiramatsu M; Kubota M; Iwasaki M; Akizawa T; Koshikawa S;
Ther Apher Dial; 2008 Feb; 12(1):19-27. PubMed ID: 18257808
[TBL] [Abstract][Full Text] [Related]
17. Pharmacokinetics of novel erythropoiesis stimulating protein (NESP) in cancer patients: preliminary report.
Heatherington AC; Schuller J; Mercer AJ
Br J Cancer; 2001 Apr; 84 Suppl 1(Suppl 1):11-6. PubMed ID: 11308269
[TBL] [Abstract][Full Text] [Related]
18. Randomized equivalence study evaluating the possibility of switching hemodialysis patients receiving subcutaneous human erythropoietin directly to intravenous darbepoetin alfa.
Chazot C; Terrat JC; Dumoulin A; Ang KS; Gassia JP; Chedid K; Maurice F; Canaud B;
Ann Pharmacother; 2009 Feb; 43(2):228-34. PubMed ID: 19407262
[TBL] [Abstract][Full Text] [Related]
19. The continuous erythropoietin receptor activator (C.E.R.A.) corrects anemia at extended administration intervals in patients with chronic kidney disease not on dialysis: results of a phase II study.
Provenzano R; Besarab A; Macdougall IC; Ellison DH; Maxwell AP; Sulowicz W; Klinger M; Rutkowski B; Correa-Rotter R; Dougherty FC;
Clin Nephrol; 2007 May; 67(5):306-17. PubMed ID: 17542340
[TBL] [Abstract][Full Text] [Related]
20. Investigation of the efficacy of a biogeneric recombinant human erythropoietin alfa in the management of renal anemia in patients on hemodialysis: a multi-center clinical trial.
Beiraghdar F; Panahi Y; Einollahi B; Nemati E; Ghadiani MH; Sahebkar A; Maghsoudi N; Marzony ET
Clin Lab; 2012; 58(7-8):737-45. PubMed ID: 22997974
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
